Key Stats for Pfizer Stock
- Past week’s performance: -1.7%
- 52-week range: $22 to $29
- Valuation model target price: $130
- Implied upside: +13.2% over 2.7 years
Value your favorite stocks like PFE with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Pfizer Inc. (PFE) had a busy week of pipeline news, but the stock still drifted lower by roughly 1.7%. The FDA approved Veppanu on May 2, a breast cancer drug developed in partnership with Arvinas. That approval gives Pfizer a new commercial product targeting estrogen receptor mutations in advanced breast cancer, a growing and underserved patient population.
Also this week, Pfizer settled patent disputes with Dexcel Pharma, Hikma, and Cipla over Vyndamax, its treatment for transthyretin amyloid cardiomyopathy. Transthyretin amyloid cardiomyopathy is a serious and underdiagnosed heart condition caused by protein buildup. Those agreements extend Vyndamax’s U.S. patent protection until 2031, and that keeps generics out of the market for at least five more years.
Pfizer also confirmed that ELREXFIO (elranatamab) met the primary endpoint in the Phase 3 MagnetisMM-5 trial for multiple myeloma. Multiple myeloma is a type of blood cancer, and this result could support a label expansion. A broader label would increase ELREXFIO’s commercial reach and add another growth driver outside of COVID-related products.
If PFE stock cannot rally on this wave of pipeline news, investors may reassess their outlook ahead of the Q1 2026 earnings call on May 5.
See analysts’ growth forecasts and price targets for PFE (It’s free) >>>
Is Pfizer Stock Undervalued?
Under valuation model assumptions realized through 12/31/28, the stock is modeled using:
- Revenue growth (CAGR): -1.6%
- Operating Margins: 35.1%
- Exit P/E Multiple: 8.8x
Based on these inputs, the model estimates a target price of $30, implying 13.2% total upside from the current share price and an annualized return of 4.7% over the next 2.7 years.
Pfizer’s biggest challenge is revenue contraction. The -1.6% revenue CAGR reflects the ongoing decline in COVID-related sales and uncertainty about new product ramp-ups. So the path back to revenue growth depends heavily on Vyndamax, ELREXFIO, and the emerging GLP1 injectable pipeline gaining commercial traction.
Operating margins of 35.1% are actually strong for a large pharmaceutical company. Pfizer’s gross margin stands at 75.8%, which gives it significant operating leverage once revenues stabilize. But achieving those margins requires revenue growth to return, and forward consensus estimates remain negative for the next two years.
The 8.8x exit multiple is historically low for Pfizer, but it reflects the market’s skepticism about the growth outlook. At only 4.7% annualized returns, the model suggests the stock is not particularly attractive for long term investors. The 6.6% dividend yield offers income, but the 125.7% payout ratio signals the dividend is not fully covered by current earnings.
What’s Driving Pfizer Stock Going Forward?
The drug pipeline is the most critical catalyst for Pfizer in 2026 and beyond. Atirmociclib, a next-generation CDK4 inhibitor, showed positive Phase 2 results in second-line metastatic breast cancer. CDK4 inhibitors block proteins that cause cancer cells to divide rapidly, and a strong Phase 3 result could create a major new commercial opportunity for Pfizer.
The GLP1 weight loss injectable also adds a new dimension to the growth story. Phase 2b trial data showed meaningful weight loss results, and the GLP1 market is among the fastest-growing segments in the pharmaceutical. But competition from Novo Nordisk and Eli Lilly is already intense, so timing and differentiation will matter.
The Vyndamax patent settlement is a near-term revenue stabilizer. The deal keeps generics out of the U.S. market until 2031, and so Vyndamax revenue should remain predictable for several years. Eliquis, Pfizer’s blockbuster blood thinner, is also now available through Mark Cuban’s Cost Plus Drugs platform, which could broaden patient access.
The Q1 2026 earnings call on May 5 is the most immediate catalyst. Investors will watch for full-year revenue guidance, progress on the cost reduction program, and pipeline timeline updates. Management’s tone on the dividend sustainability will also matter, given the elevated 125.7% payout ratio.
Estimate a company’s fair value instantly (Free with TIKR) >>>
Should You Invest in Pfizer?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up PFE, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track PFE alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Pfizer stock on TIKR Free→
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
